AI brief of an SEC Form 8-K · Amphstar Pharmaceuticals (AMPH)

Amphastar signs new employment agreements with two executives, including a board member

Neutral Impact 2 of 5 leadership Written later

On March 3, 2026, Amphastar entered employment agreements with Jacob Liawatidewi, Executive Vice President of Corporate Administration Center, Secretary and board member, and Rong Zhou, Senior Executive Vice President of Production Center. The agreements set base salaries, target bonuses, and severance terms that would apply if an executive is terminated without cause, does not have a renewal, or resigns for good reason, with enhanced terms after a change in control.

Key points

  • Liawatidewi base salary is $525,800 with a target annual bonus of 55% of salary; Zhou base salary is $590,000 with a target bonus of 53% of salary.
  • On a qualifying termination, each executive receives a lump sum of two times the highest base salary of the prior 12 months plus the average annual bonus for the two most recent fiscal years, up to 12 months of health premium payments, and
  • Terms within one year after a change in control add a second lump-sum payment of the same formula and an extra 12 months of health premium payments.
  • The agreements have a one-year initial term with automatic one-year renewals; the form of agreement is filed as Exhibit 10.1, and the report is dated March 6, 2026.

The filing

CompanyAmphstar Pharmaceuticals (AMPH)
Form8-K, current report
Filed with the SECMar 6, 2026, 4:17 PM ET
Accession number0001297184-26-000015

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.